Diazoxide choline controlled release - Soleno Therapeutics
Alternative Names: C601; C602; DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release; Diazoxide-choline-controlled-release-Essentialis; VYKAT XRLatest Information Update: 22 Apr 2025
At a glance
- Originator Essentialis
- Developer Essentialis; Soleno Therapeutics
- Class Antihyperlipidaemics; Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Chlorobenzenes; Ethanolamines; Obesity therapies; Peripheral vasodilators; Small molecules; Sulfonamides
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Prader-Willi syndrome
- Phase II Hypertriglyceridaemia
- Discontinued Hypoglycaemia; Obesity
Most Recent Events
- 14 Apr 2025 Launched for Prader-Willi syndrome (In the elderly, In adults, In adolescents, In children) in USA (PO)
- 26 Mar 2025 Soleno Therapeutics plans to launch Diazoxide choline controlled release for the treatment of Prader-Willi syndrome in the US beginning in April 2025
- 26 Mar 2025 Registered for Prader-Willi syndrome (In adolescents, In children, In the elderly, In adults) in USA (PO)